<DOC>
	<DOCNO>NCT02452814</DOCNO>
	<brief_summary>Long Term Observational Extension Study Designed Monitor Long-Term Efficacy Safety Miravirsen Sodium Combination Telaprevir Ribavirin Subjects Chronic Hepatitis C Virus Genotype 1 Infection</brief_summary>
	<brief_title>Long Term Extension Study Designed Monitor Long-Term Efficacy Safety Miravirsen Sodium Combination With Telaprevir Ribavirin Subjects With Chronic Hepatitis C Virus Genotype 1 Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Participated Study SPC3649205 ( would include complete study SPC3649205 , discontinue terminate study early whatever reason ( include treatment failure ) opt receive approved therapy treatment HCV infection ) . Those unwilling provide inform consent participation study . Subjects receive investigational drug therapy discontinuation , termination , successful completion Study SPC3649205 .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>